- t2cure’s cell therapy is available through cooperating clinical centres
- t2cure cooperates with experienced partners in research and in the industry.
- t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
- t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.
Investors
t2cure is a privately held limited liability company (GmbH) incorporated in Frankfurt am Main, Germany. Company received its first financing in July 2006 with EF Investments S.a.r.l., Luxembourg, as lead investor. KfW, Kreditanstalt für Wiederaufbau, joined as a new co-lead investor with Entrepreneurs Fund in another financing round increasing total funds to Euro 3.5M.